New Anticoagulants

ABSTRACT

The anticoagulant drugs have an essential role in the prevention and treatment of thromboembolic diseases. The currently available anticoagulants have several limitations, including a narrow therapeutic window, the risk of bleeding complications and, for some drugs, the need for laboratory monitoring and parenteral administration. These limitations make the case for the development of new anticoagulants. An ideal anticoagulant should be effective, safe, simple to use, and widely applicable. The new anticoagulants currently under investigation are obtained by molecular technology that makes it possible to target their effect toward a selected step of the coagulation cascade. Based on their target, new anticoagulants can be classified into three groups: inhibitors of activation of coagulation, inhibitors of propagation of coagulation, and inhibitors of thrombin formation. Several new anticoagulants currently are in different phases of development. Some of them have been approved for clinical use, others are in advanced phase of clinical development, and some are still in the initial phase of investigation.

Anticoagulant therapy - antithrombotic therapy - anticoagulants - direct thrombin inhibitors - factor Xa inhibitors

REFERENCES

• 1 Hirsh J, Raschke R. Heparin and low-molecular-weight heparin.  Chest. 2004;  126 S188-S203
• 2 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists.  Chest. 2004;  126 204S-233S
• 3 Weitz J I, Hirsh J, Samama M M. New anticoagulant drugs.  Chest. 2004;  126 265S-286S
• 4 Furie B, Furie B C. Molecular and cellular biology of blood coagulation.  N Engl J Med. 1992;  326 800-806
• 5 Mann K G, Butenas S, Brummel K. The dynamics of thrombin formation.  Arterioscler Thromb Vasc Biol. 2003;  23 17-25
• 6 Abraham E, Reinhart K, Svoboda P et al.. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.  Crit Care Med. 2001;  29 2081-2089
• 7 Abraham E, Reinhart K, Opal S et al.. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.  JAMA. 2003;  290 238-247
• 8 Taylor Jr F B. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon.  Haemostasis. 1996;  26 83-91
• 9 Jang Y, Guzman L A, Lincoff A M et al.. Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.  Circulation. 1995;  92 3041-3050
• 10 Lincoff A M. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: a randomized, double-blinded, dose-escalation trial- assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial.  J Am Coll Cardiol. 2000;  36 312 , (abst)
• 11 Cappello M, Vlasuk G P, Bergum P W, Huang S, Hotez P J. Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa.  Proc Natl Acad Sci USA. 1995;  92 6152-6156
• 12 Stassen P, Bergum P W, Gansemans Y et al.. Anticoagulant repertoire of the hookworm Ancylostoma caninum .  Proc Natl Acad Sci USA. 1996;  93 2149-2154
• 13 Lee A, Agnelli G, Bűller H et al.. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.  Circulation. 2001;  104 74-78
• 14 Rezaie A R. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex.  Blood. 2001;  97 2308-2313
• 15 Brufatto N, Nesheim M E. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation.  J Biol Chem. 2001;  276 17663-17671
• 16 Boneu B, Necciari J, Cariou R et al.. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man.  Thromb Haemost. 1995;  74 1468-1473
• 17 Eriksson B I, Bauer K A, Lassen M R, Turpie A G. Steering Committee of the Pentasaccharide in hip fracture . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med. 2001;  345 1298-1304
• 18 Lassen M R, Bauer K A, Eriksson B I, Turpie A G. European Pentasaccharide elective surgery study (EPHESUS) Steering Committee . Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  Lancet. 2002;  359 1715-1720
• 19 Turpie A G, Bauer K A, Eriksson B I, Lassen M R. PENTATHLON 2000 Steering Committee . Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  Lancet. 2002;  359 1721-1726
• 20 Bauer K A, Eriksson B I, Lassen M R, Turpie A G. Steering Committee of the Pentasaccharide in major knee surgery study . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1310
• 21 Turpie A G, Bauer K A, Eriksson B I, Lassen M R. Fondaparinux versus enoxaparin for prevention of venous thromboembolism in major orthopaedic surgery. A meta-analysis of 4 randomized, double blind studies.  Arch Intern Med. 2002;  162 1833-1840
• 22 Büller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease.  Chest. 2004;  126 S401-S428
• 23 Eriksson B I, Lassen M R. PENTasaccharide in Hip-FRAture Surgery Plus Investigators . Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo controlled, double-blind study.  Arch Intern Med. 2003;  163 1337-1342
• 24 Agnelli G, Bergqvist D, Cohen A, Gallus A, Gent M. A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study.  J Thromb Haemost. 2003;  1(suppl) OC006 , (abst)
• 25 Cohen A T, Gallus A S, Lassen M R et al.. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis).  J Thromb Haemost. 2003;  1(suppl) 2046 , (abst)
• 26 Buller H R, Davidson B L, Decousus H et al.. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.  Ann Intern Med. 2004;  140 867-873
• 27 The MATISSE Investigators . Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.  N Engl J Med. 2003;  349 1695-1702
• 28 Coussement P K, Bassand J P, Convens C et al.. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study.  Eur Heart J. 2001;  22 1716-1724
• 29 Ferguson J J. Meeting highlights: American Heart Association scientific sessions 2001.  Circulation. 2002;  105 e37-e41
• 30 Herbert J M, Herault J P, Bernat A et al.. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.  Blood. 1998;  91 4197-4205
• 31 Persist Investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation.  J Thromb Haemost. 2004;  2 47-53
• 32 Lassen M R, Davidson B L, Gallus A et al.. A phase II, randomized, double blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for prevention of deep vein thrombosis in knee-replacement surgery-on behalf of the Razaxaban Investigators.  Blood. 2003;  102(suppl) 11 , (abst 41)
• 33 Esmon C T, Ding W, Yasuhiro K et al.. The protein C pathway: new insights.  Thromb Haemost. 1997;  78 70-74
• 34 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 35 Moll S, Lindley C, Pescatore S et al.. Phase 1 study of a novel recombinant human soluble thrombomodulin ART-123.  J Thromb Haemost. 2004;  2 1745-1751
• 36 Kearon C, Comp P, Douketis J et al.. A dose-response study of a recombinant soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.  J Thromb Haemost. 2005;  3 962-968
• 37 Weitz J I, Bűller H R. Direct thrombin inhibitors in acute coronary syndromes: present and future.  Circulation. 2002;  105 1004-1011
• 38 Weitz J I, Crowther M. Direct thrombin inhibitors.  Thromb Res. 2002;  106 V275-V284
• 39 Agnelli G, Cosmi B, Di Filippo P et al.. A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture.  Thromb Haemost. 1992;  67 203-208
• 40 Taliani M R, Agnelli G, Nenci G G, Gianese F. Dermatan suphate in patients with heparin induced thrombocytopenia.  Br J Haematol. 1999;  104 87-89
• 41 Wallis R B. Hirudins: from leeches to man.  Semin Thromb Hemost. 1996;  22 185-196
• 42 Toschi V, Lettino M, Gallo R, Badimon J J, Chesebro J H. Biochemistry and biology of hirudin.  Coron Artery Dis. 1996;  7 420-428
• 43 Lefevre G, Duval M, Gauron S et al.. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.  Clin Pharmacol Ther. 1997;  62 50-59
• 44 Eriksson B I, Ekman S, Lindbratt S et al.. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am. 1997;  79 326-333
• 45 Eriksson B I, Wille-Jørgensen P, Kalebo P et al.. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335
• 46 Organization to Assess Strategies for Ischemic Syndromes Investigators . Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study: Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.  Circulation. 1997;  96 769-777
• 47 Organization to Assess Strategies for Ischemic Syndromes Investigators . Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.  Lancet. 1999;  353 429-438
• 48 Antman E M. and the TIMI 9A Investigators . Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.  Circulation. 1994;  90 1624-1630
• 49 Neuhaus K L, von Essen R, Tebbe U et al.. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).  Circulation. 1994;  90 1638-1642
• 50 The GUSTO IIa Investigators . Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa investigators.  Circulation. 1994;  90 1631-1637
• 51 The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: the GUSTO Investigators.  N Engl J Med. 1993;  329 673-682
• 52 The GUSTO IIb Investigators . A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes: the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators.  N Engl J Med. 1996;  335 775-782
• 53 Metz B K, White H D, Granger C B et al.. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial: Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.  J Am Coll Cardiol. 1998;  31 1493-1498
• 54 Serruys P W, Herrman J P, Simon R et al.. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators.  N Engl J Med. 1995;  333 757-763
• 55 Maraganore J M, Bourdon P, Jablonski J, Ramachandran K L, Fenton II J W. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.  Biochemistry. 1990;  29 7095-7101
• 56 Ginsberg J S, Michael T, Nurmohamed M T et al.. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery.  Circulation. 1994;  90 2385-2389
• 57 Hursting M J, Alford K L, Becker J C et al.. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor.  Semin Thromb Hemost. 1997;  23 503-516
• 58 Banner D W, Hadvary P. Inhibitor binding to thrombin: x-ray crystallographic studies.  Adv Exp Med Biol. 1993;  340 27-33
• 59 Swan S K, Hursting M J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.  Pharmacotherapy. 2000;  20 318-329
• 60 Gustafsson D, Nystrom J E, Carlsson S et al.. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res. 2001;  101 171-181
• 61 Eriksson B I, Bergqvist D, Kalebo P et al.. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.  Lancet. 2002;  360 1441-1447
• 62 Eriksson B I, Agnelli G, Cohen A T et al.. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee joint replacement.  Thromb Haemost. 2003;  89 288-296
• 63 Eriksson B I, Agnelli G, Cohen A T et al.. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. The EXPRESS study.  J Thromb Haemost. 2003;  1 2490-2496
• 64 Francis C W, Davidson B L, Berkowitz S D et al.. Ximelagatran versus warfarin for the prevention of VTE after total knee arthroplasty.  Ann Intern Med. 2002;  137 648-655
• 65 Francis C W, Berkowitz S D, Comp P C et al.. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.  N Engl J Med. 2003;  349 1703-1712
• 66 Colwell C W, Berkowitz S D, Davidson B L et al.. Randomized, double blind comparison of Ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) EXULT-b.  Blood. 2003;  102 11 , (abst 39)
• 67 Eriksson H, Wahlander K, Gustafsson D, Welin L T, Frison L, Schulman S. Thrive Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.  J Thromb Haemost. 2003;  1 41-47
• 68 Fiessinger J N, Huisman M V, Davidson B L. the THRIVE Investigators . Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis a randomized trial.  JAMA. 2005;  293 681-689
• 69 Schulman S, Wahlander K, Lundstrom T, Clason S B, Eriksson H. for the THRIVE III Investigators . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.  N Engl J Med. 2003;  349 1713-1721
• 70 Petersen P, Grind M, Adler J et al.. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding tolerability, and safety study.  J Am Coll Cardiol. 2003;  41 1445-1451
• 71 Executive Steering Committee on behalf of the SPORTIF III Investigators . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized trial.  Lancet. 2003;  362 1691-1698
• 72 SPORTIF Executive Steering Committee for the SPORTIF V Investigators . Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial.  JAMA. 2005;  293 690-698
• 73 Halperin J L. for the Executive Steering Committee, SPORTIF III and V Study Investigators . Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).  Am Heart J. 2003;  146 431-438
• 74 Wallentin L, Wilcox R G, Weaver W D et al.. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.  Lancet. 2003;  362 789-797
• 75 Eriksson B I, Dahl O E, Ahnfelt I et al.. Dose escalating safety of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: Bistro I.  J Thromb Haemost. 2004;  2 1573-1580
• 76 Eriksson B I, Dahl O E, Büller H R et al.. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for the prevention of thromboembolic events following total hip or knee replacement: the Bistro II randomized trial.  J Thromb Haemost. 2005;  3 103-111